Time of Oxytocin Initiation at 2nd Stage of Labor and Adverse Outcomes
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorRambam Health Care Campus
About this trial
Early oxytocin administration at the 2nd stage of labor is associated with a higher rate of vaginal delivery, shorter second stage duration, and fewer adverse maternal and neonatal outcomes.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Singleton pregnancy
Maternal age ≥ 18 years' old
Oxytocin administration initiated or renewed during second stage of labor
Disqualifiers
Maternal age < 18 years' old
Multiple gestation pregnancy
Known fetal malformations
Uterine scar
Trial design
Design model
Parallel
Treatments tested in this trial
Oxytocin
DrugNative oxytocin analog
Treatment groups
120 Participants
are divided into 2 treatment groupsGroup A: Immediate oxytocinExperimental treatment 1 intervention
Group B: Delayed oxytocinOther 1 intervention
Trial outcomes
Primary outcomes
1
Mode of delivery
Vaginal or instrumental or cesarean
Time frame
DeliverySecondary outcomes
1
2nd stage duration
Minutes
Time frame
Delivery2
intrapartum fever
Rate of chorioamnionitis
Time frame
Delivery or 48 hours postpartum3
Meconium stain
Rate
Time frame
Delivery4
Postpartum hemorrhage
more than 500 ml following vaginal delivery or more than 1000 ml at cesarean delivery
Time frame
DeliverySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov